Nanotechnology for molecular imaging and targeted therapy.

The recent emergence of “molecular imaging” as an integrated discipline in academic medical centers has set the stage for an evolutionary leap in diagnostic imaging and therapy. 1 Molecular imaging is not a substitute for the traditional process of image formation and interpretation, but is intended to improve diagnostic accuracy and sensitivity by providing an in vivo analog of immunocytochemistry or in situ hybridization. It is less concerned with native image contrast or resolution, which are keys for depicting the effects of the disease on surrounding normal tissues, but rather, it seeks to enhance the conspicuity of microscopic pathologies by targeting the molecular components or processes that represent actual mechanisms of disease. Moreover, imaging will become crucial for in vivo characterization of the complex behaviors of disease in time and space that will tell us: where it is, how big it is, how fast it is developing, how many molecular processes are contributing simultaneously, what to treat it with, how it is responding to therapy, and how it is changing. Elements fundamental to the growth of molecular imaging are exemplified in summary statements from the second Biomedical Imaging Symposium: Visualizing the Future of Biology and Medicine (Available at: http://www.becon1. nih.gov/symposium1999.htm), which convened at the National Institutes for Health (NIH) on June 25 and 26, 1999, and was cosponsored by the Biomedical Engineering Consortium (BECON), the Radiological Society of North America, and the American Institute of Medical and Biological Engineering. The goals of the Symposium were to: (1) “identify the most important challenges and opportunities in biomedical imaging science,” and (2) “develop strategies for integrating imaging science with biological and medical research.” The formation of the BECON was followed by a Congressional mandate to establish a new National Institute for Biomedical Imaging and Bioengineering devoted to the development of novel technologies, including molecular imaging and therapeutics, without the traditional restrictions of hypothesis-driven research. The BECON symposium identified 5 action items critical to achieving these goals: ● Implementation of multidisciplinary research programs, especially in the area of molecular imaging or image guided therapy; ● Development of new imaging technologies, probes, and

[1]  Stasia A. Anderson,et al.  Magnetic resonance contrast enhancement of neovasculature with αvβ3‐targeted nanoparticles , 2000 .

[2]  S. Davis,et al.  Biomedical applications of nanotechnology--implications for drug targeting and gene therapy. , 1997, Trends in biotechnology.

[3]  Weissleder,et al.  Approaches and agents for imaging the vascular system. , 1999, Advanced drug delivery reviews.

[4]  R Weissleder,et al.  In vivo imaging of gene and cell therapies. , 2001, Experimental hematology.

[5]  J. Debatin,et al.  Magnetic Resonance Imaging of Atherosclerotic Plaque With Ultrasmall Superparamagnetic Particles of Iron Oxide in Hyperlipidemic Rabbits , 2001, Circulation.

[6]  N. Pandian,et al.  Enhanced visualization of intravascular and left atrial appendage thrombus with the use of a thrombus-targeting ultrasonographic contrast agent (MRX-408A1): In vivo experimental echocardiographic studies. , 1999, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[7]  R V Shohet,et al.  Echocardiographic destruction of albumin microbubbles directs gene delivery to the myocardium. , 2000, Circulation.

[8]  J. G. Miller,et al.  In vivo molecular imaging of stretch-induced tissue factor in carotid arteries with ligand-targeted nanoparticles. , 2000, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[9]  Jianpeng Ma,et al.  Molecular dynamics analysis of a buckyball–antibody complex , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Sheng-Kwei Song,et al.  High‐resolution MRI characterization of human thrombus using a novel fibrin‐targeted paramagnetic nanoparticle contrast agent , 2000, Magnetic resonance in medicine.

[11]  D. McPherson,et al.  In vivo targeting of acoustically reflective liposomes for intravascular and transvascular ultrasonic enhancement. , 1999, Journal of the American College of Cardiology.

[12]  R. Virmani,et al.  Sustained Reduction of In-Stent Neointimal Growth With the Use of a Novel Systemic Nanoparticle Paclitaxel , 2002, Circulation.

[13]  R Weissleder,et al.  High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. , 1999, Bioconjugate chemistry.

[14]  S A Wickline,et al.  Novel MRI Contrast Agent for Molecular Imaging of Fibrin: Implications for Detecting Vulnerable Plaques , 2001, Circulation.

[15]  J. G. Miller,et al.  A novel site-targeted ultrasonic contrast agent with broad biomedical application. , 1996, Circulation.

[16]  P C Lauterbur,et al.  Dendrimer‐based metal chelates: A new class of magnetic resonance imaging contrast agents , 1994, Magnetic resonance in medicine.

[17]  Alexander Petrovsky,et al.  Magnetic resonance imaging of inducible E-selectin expression in human endothelial cell culture. , 2002, Bioconjugate chemistry.

[18]  J. Baker,et al.  Substituted beta-cyclodextrins interact with PAMAM dendrimer-DNA complexes and modify transfection efficiency. , 2001, Biochemical and biophysical research communications.

[19]  E J Topol,et al.  Local intraluminal infusion of biodegradable polymeric nanoparticles. A novel approach for prolonged drug delivery after balloon angioplasty. , 1996, Circulation.

[20]  M. Schwaiger,et al.  Uptake of Radiolabeled 2′-Fluoro-2′-Deoxy-5-Iodo-1-&bgr;-d-Arabinofuranosyluracil in Cardiac Cells After Adenoviral Transfer of the Herpesvirus Thymidine Kinase Gene: The Cellular Basis for Cardiac Gene Imaging , 2000, Circulation.

[21]  S A Wickline,et al.  Molecular imaging of stretch-induced tissue factor expression in carotid arteries with intravascular ultrasound. , 2000, Investigative radiology.

[22]  F. Blankenberg,et al.  Noninvasive strategies to image cardiovascular apoptosis. , 2001, Cardiology clinics.

[23]  M. Bednarski,et al.  Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. , 1998, Nature medicine.

[24]  Peter van Gelderen,et al.  Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells , 2001, Nature Biotechnology.

[25]  J. G. Miller,et al.  In vitro characterization of a novel, tissue-targeted ultrasonic contrast system with acoustic microscopy. , 1998, The Journal of the Acoustical Society of America.

[26]  Ji Song,et al.  Influence of injection site, microvascular pressure and ultrasound variables on microbubble-mediated delivery of microspheres to muscle. , 2002, Journal of the American College of Cardiology.

[27]  E. Unger,et al.  Ultrasound enhances gene expression of liposomal transfection. , 1997, Investigative radiology.

[28]  Erkki Ruoslahti,et al.  Nanocrystal targeting in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[29]  T. Kowalewski,et al.  Two-dimensional, shell-cross-linked nanoparticle arrays. , 2001, Journal of the American Chemical Society.

[30]  R. Müller,et al.  Nanostructured lipid matrices for improved microencapsulation of drugs. , 2002, International journal of pharmaceutics.

[31]  Ralph Weissleder,et al.  Tat peptide directs enhanced clearance and hepatic permeability of magnetic nanoparticles. , 2002, Bioconjugate chemistry.

[32]  Kerry K. Karukstis,et al.  Targeted Antiproliferative Drug Delivery to Vascular Smooth Muscle Cells With a Magnetic Resonance Imaging Nanoparticle Contrast Agent: Implications for Rational Therapy of Restenosis , 2002, Circulation.

[33]  J. G. Miller,et al.  High-frequency ultrasonic detection of thrombi with a targeted contrast system. , 1997, Ultrasound in medicine & biology.

[34]  J A Frank,et al.  Synthesis and relaxometry of high‐generation (G = 5, 7, 9, and 10) PAMAM dendrimer‐DOTA‐gadolinium chelates , 1999, Journal of magnetic resonance imaging : JMRI.